WuXi XDC Partners with GeneQuantum for ADC Development
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...
HKG: 2269
WuXi Biologics’ Shanghai Subsidiary Removed from US UVL
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...
WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...
Harbour BioMed and WuXi Biologics Announce Strategic Collaboration
Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...
WuXi Biologics Partners with Toregem BioPharma on Anti-USAG-1 Monoclonal Antibody
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
WuXi Biologics Removed from US Unverified List Amid Ongoing Restrictions
The US Commerce Department’s Bureau of Industry and Security (BIS) has updated its Unverified List...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
WuXi Biologics Partners with Elpiscience for Macromolecule Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...
WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial
China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...
WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (SHA: 603259),...
Wuxi Biologics Set to Be Removed from US Restricted Trade List
Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...
WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...